VIR — Vir Biotechnology Inc

Vir Biotechnology Inc (VIR) is a biotechnology company listed on NASDAQ. It is led by Marianne De Backer M.B.A., M.Sc., Ph.D., based in 1800 Owens Street, San Francisco, CA, United States, 94158, with about 367 employees. Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Latest reported VIR revenue for 2025-09-30 was $240.0K. Net income was -$163.1M. Revenue was down 80.2% from 2025-06-30 to 2025-09-30. VIR currently screens at market cap $1.45B.

Use this VIR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VIR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VIR SEC filings page. Lician reads the product cache first so this HTML stays unique to Vir Biotechnology Inc even when a live quote feed is slow.